Summary: Jennifer Quint, Thorax's Journal Club editor, talks to David Jablons, University of California San Francisco, and consultant for Life Technologies, about his assay to predict survival in resected non-squamous, non-small-cell lung cancer. See also: A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies
